Anrukinzumab
Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma[1][2][3].
Product Specifications
CAS Number
[910649-32-0]
Product Name Alternative
IMA-638
UNSPSC
12352203
Target
Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/anrukinzumab.html
Purity
98.64
Solubility
10 mM in DMSO
Smiles
[Anrukinzumab]
Molecular Weight
(145.38 kDa)
References & Citations
[1]Bree A, et al. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol. 2007 May;119 (5) :1251-7. |[2]Reinisch W, et al. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut. 2015 Jun;64 (6) :894-900. |[3]Elias JA, et al. IL-13 in asthma. The successful integration of lessons from mice and humans. Am J Respir Crit Care Med. 2011 Apr 15;183 (8) :957-8.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS9946005 Inquire
Goat Proprotein Convertase Subtilisin/Kexin Type 4 (PCSK4) ELISA Kit
Ask
View Details